Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2554 - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Kaissa Ouali

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

K. Ouali1, R. Cohen1, A. Turpin2, C. Neuzillet3, B. Rousseau4, M. Garcia-Larnicol5, C. Tournigand6, E. Samalin7, J. Taieb8, T. André1

Author affiliations

  • 1 Medical Oncology, Saint-Antoine hospital, AP-HP, 75012 - Paris/FR
  • 2 Medical Oncology, CHRU Lille, 59037 - Lille/FR
  • 3 Medical Oncology, Curie institute, 92210 - Saint Cloud/FR
  • 4 Medicine - Solid Tumor Division, Mortimer B. Zuckerman Research Center /Memorial Sloan Kettering Cancer Center, 10065 - New-York/US
  • 5 Gercor, GERCOR, 75011 - Paris/FR
  • 6 Medical Oncology, Henri Mondor hospital, 94010 - Créteil/FR
  • 7 Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 8 Department Of Gastroenterology And Digestive Oncology, European Georges Pompidou Hospital, 75015 - Paris/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2554

Background

The IDEA study showed that the type and duration of adjuvant chemotherapy in stage III colon cancer (CC) could be adjusted according to level of risk (Grothey et al., New Engl J Med 2018). One year after the publication of IDEA study, we performed an audit of real-life practices in France.

Methods

We conducted an online anonymized nationwide survey from January 30, 2019 to March 31, 2019. An invitation email followed by reminders every 2 weeks was sent to clinicians using the oncology cooperative groups GERCOR, FFCD and GI UNICANCER mailing lists. All of the answers were declarative, individual, and anonymized. Proportions were compared using chi-squared test.

Results

A total of 213 physicians answered the survey: 31% worked in an academic hospital, 27% in a general hospital, 26% in a comprehensive cancer center and 16% in a private clinic. Main responders were gastroenterologists (51%) or medical oncologists (39%). 47% of physicians took care of more than 12 stage III CC patients per year. For low risk stage III CC (T1-T3 and N1), 81% preferred a 3-month duration of treatment, and 74% used capecitabine plus oxaliplatine (CAPOX) as the standard regimen. 66% of CAPOX for 3 months were realized without central venous access device, which was necessary during treatment in less than 25% of cases according to 68% of the responders. Physicians choosing 6-month duration of adjuvant treatment for low risk stage III CC were more often medical oncologists (58% versus 35%, P = 0.009) or working in a general hospital (48% versus 22%, P = 0.001); no significant difference was observed considering years of professional experience or the number of patients treated per year. For high risk stage III CC (T4 and/or N2), 99.5% of responders considered that adjuvant chemotherapy should be prescribed for 6 months, and 94% with FOLFOX.

Conclusions

One year after the publication of the IDEA study, 3 months of adjuvant chemotherapy with CAPOX has been mainly integrated as a new standard of care for low risk stage III CC patients in daily practice whereas 6 months of FOLFOX remains the standard of care of high risk stage III CC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

GERCOR.

Funding

Has not received any funding.

Disclosure

B. Rousseau: Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution), Travel / Accommodation / Expenses: Servier; Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses: Gilead; Research grant / Funding (institution), Travel / Accommodation / Expenses: AbbVie. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.